TrialPath
Recruiting

WATER IV PCa (AS Sub-study)

NCT07650448 · PROCEPT BioRobotics
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
WATER IV Prostate Cancer: Aquablation Versus Active Surveillance for the Treatment of Localized Prostate Cancer
About this study
The WATER IV AS sub-study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with low to intermediate risk localized prostate cancer who are candidates for active surveillance. Participants will be randomized to either Aquablation Therapy or active surveillance and followed up to 10 years.
Eligibility criteria
Inclusion Criteria: 1. Biological male with age ≥ 45 years at the time of consent 2. Biopsy positive Grade Group 2 prostate cancer or biopsy positive Grade Group 1 MRI visible lesion (PI-RADS/Likert ≥ 3) 3. First prostate cancer diagnoses within 18 months (545 days) of consent 4. Are candidates for active surveillance 5. Clinical Stage ≤ T2c 6. PSA \< 15 ng/ml 7. Prostate volume ≥25 ml Exclusion Criteria: 1. Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy. 2. Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment. 3. Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion. 4. Patient is unwilling to accept a blood transfusion if required. 5. Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as: 5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease). 6\. Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated. 7\. Patient currently participating in other studies unless approved by Sponsor in writing. 8\. More than one complete biopsy beyond the diagnostic biopsy comprising both a systematic biopsy and biopsy of any MRI visible lesion (PI-RADS/Likert ≥ 3). 9\. GG2 disease with PSA ≥ 10 OR stage ≥ T2b OR ≥ 50% of biopsy cores positive (multiple cores taken from any MRI visible lesion are counted as one continuous core).
Study design
Enrollment target: 333 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-11
Estimated completion: 2038-12
Last updated: 2026-11-06
Interventions
Device: Aquablation TherapyOther: Active Surveillance
Primary outcomes
  • • Freedom from GG ≥ 2 (12 Months)
Sponsor
PROCEPT BioRobotics · industry
Contacts & investigators
ContactAngela Lee · contact · a.lee@procept-biorobotics.com · 650-232-7215
All locations (28)
Arizona State Urological InstituteNot Yet Recruiting
Chandler, Arizona, United States
University of Southern CaliforniaRecruiting
Los Angeles, California, United States
Tri Valley UrologyNot Yet Recruiting
Murrieta, California, United States
Boulder Medical CenterNot Yet Recruiting
Boulder, Colorado, United States
Advanced ResearchRecruiting
Delray Beach, Florida, United States
University of MiamiNot Yet Recruiting
Miami, Florida, United States
Trophy Point UrologyNot Yet Recruiting
Tampa, Florida, United States
Georgia UrologyRecruiting
Atlanta, Georgia, United States
Mountain View HospitalRecruiting
Idaho Falls, Idaho, United States
University of ChicagoNot Yet Recruiting
Chicago, Illinois, United States
Endeavor HealthRecruiting
Glenview, Illinois, United States
Johns Hopkins UniversityNot Yet Recruiting
Baltimore, Maryland, United States
Kansas City Urology CareNot Yet Recruiting
North Kansas City, Missouri, United States
Kearney Urology CenterRecruiting
Kearney, Nebraska, United States
Adult & Pediatric UrologyRecruiting
Omaha, Nebraska, United States
Hackensack University Medical CenterNot Yet Recruiting
Hackensack, New Jersey, United States
Albany Medical CollegeNot Yet Recruiting
Albany, New York, United States
Integrated Medical Professionals, PLLCRecruiting
New York, New York, United States
University of Rochester Medical CenterNot Yet Recruiting
Rochester, New York, United States
Cleveland Clinic FoundationNot Yet Recruiting
Cleveland, Ohio, United States
MUSC Hollings Cancer CenterRecruiting
Charleston, South Carolina, United States
Tidelands Health UrologyNot Yet Recruiting
Murrells Inlet, South Carolina, United States
Midtown UrologyRecruiting
Austin, Texas, United States
Urology AustinRecruiting
Austin, Texas, United States
Urology Clinics of North TexasRecruiting
Dallas, Texas, United States
Potomac UrologyNot Yet Recruiting
Alexandria, Virginia, United States
Advocate Aurora Research InstituteNot Yet Recruiting
Sheboygan, Wisconsin, United States
Chinese University of Hong KongNot Yet Recruiting
Shatin, Hong Kong